Developer docs
API playgroundTry for free, no card

Search company profiles

Brainreader

Full company profile

uuid0002ci7

Namestring
Brainreader
Legal namestring
Brainreader A/S
Websiteurl
brainreader.net
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Brainreader A/S is a Danish medtech company founded in 2011 by Jamila Ahdidan, PhD, that develops Neuroreader, an FDA-cleared and CE-marked AI-enabled software for automated brain volumetric analysis from routine MRI scans. The software segments and quantifies 83 brain regions in under 10 minutes, compares measured volumes against an FDA-cleared normative database of healthy brain tissue, and outputs reports containing volumes, percentiles, and Z-scores to support diagnosis and longitudinal monitoring of neurodegenerative conditions including Alzheimer's disease, mild cognitive impairment, traumatic brain injury, and frontotemporal dementia. Workflow integration is achieved via PACS mediation server or web upload with no hardware costs, enabling adoption as a routine MRI add-on.

The company sells to hospitals and health systems, imaging centers, neurology and radiology practices, and academic/research institutions via a pay-per-use model (approximately $70 per scan, reimbursable under CPT code 76377) and subscription licensing. Its core go-to-market combines direct enterprise sales — recently anchored by a US sales team led by Head of U.S. Sales Steve Green and a consulting CMO, Dr. Cyrus Raji — with channel distribution through INFINITT North America (access to 6,500+ PACS installations across 55 countries) and Rad Alliance. Notable clinical and research partners include UPMC, Medical College of Wisconsin, Washington University in St. Louis, Pacific Neuroscience Institute, and UCLA.

Brainreader is venture-backed (Insero, Investo Capital, Bevica Innovation, CBC Investment Group, and lead Series A investor Dahlgren Capital in May 2025 at $7.3M), ISO 13485:2016 certified, HIPAA-compliant, and operates from Aalborg, Denmark with a US headquarters in Tampa, Florida. A flagship commercial relationship is its exclusive partnership with Phenome Health on the Beyond the Human Genome Project, a ten-year, one-million-participant brain health trial.

Short descriptiontext

Brainreader is a Danish medtech company (founded 2011) that sells Neuroreader, an FDA-cleared AI software that quantifies 83 brain regions from routine MRI scans in under 10 minutes to support diagnosis and monitoring of neurodegenerative diseases for hospitals, imaging centers, and neurology/radiology practices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAalborg, Denmark
HQ citystring
Aalborg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI brain volumetrics, medical imaging software, neurodegenerative disease detection, MRI volumetric analysis, brain health diagnostics
Industry2 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Medical Imaging Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS/Per-Use Brain Volumetric Analysis
TypeUsage Based
Description

Pay-per-use model where healthcare facilities pay per MRI scan analyzed. Simple pay-per-use pricing with no hardware or setup costs. Also available via subscription model tailored to healthcare organization preferences.

brainreader.net
2Subscription Licensing
TypeSubscription Recurring
Description

Annual or multi-year subscription licensing options for hospitals, imaging centers, and radiology departments.

brainreader.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details2 tiers
1Pay-per-use model
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Approximately $70 per scan analysis; reimbursable by insurance with CPT code 76377. No hardware or setup costs required.

brainreader.net
2Subscription model for healthcare organizations
ModelSubscriptionBilling cadenceAnnual
Notes

Tailored to healthcare organization's wishes - pay-per-use or subscription model available. Pricing provided in quotation.

brainreader.net
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Neuroreader®
Description

FDA-cleared and CE-marked AI-powered brain volumetric analysis software that quantifies 83 brain regions from routine MRI scans in less than 10 minutes for neurodegenerative disease detection.

brainreader.net
Core offering1 text field

Brainreader develops Neuroreader, an FDA-cleared and CE-marked AI-powered medical software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. The platform provides objective volumetric measurements and statistical comparisons against an FDA-cleared normative database of healthy brain tissue, supporting detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, traumatic brain injury, and frontotemporal dementia. The software integrates directly into existing PACS workflows via web upload or on-site mediation server, eliminating the need for additional hardware.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reports generated in under 10 minutes, significantly faster than manual expert anatomical tracings which take 30+ minutes
+3 more records
Product overview1 text field

Brainreader offers a single unified product platform centered on Neuroreader, an FDA-cleared and CE-marked AI-powered medical software for automated brain volumetric analysis. The platform provides quantitative MRI analysis by measuring 83 brain regions and comparing results against an FDA-cleared normative database, generating automated reports in under 10 minutes. Supporting resources include patient-facing educational materials, sample reports, and published case studies demonstrating clinical applications for Alzheimer's disease, traumatic brain injury, and other neurodegenerative conditions.

Product and service4 records
1Neuroreader
CategoryMedical Imaging Software
Description

FDA-cleared and CE-marked AI-powered brain volumetric analysis software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. Provides objective quantitative measurements, normative comparisons via an FDA-cleared healthy-brain database, and automated reports to support diagnosis and monitoring of neurodegenerative diseases including Alzheimer's, dementia, and traumatic brain injury. Targeted at hospitals, imaging centers, neurology and radiology practices, and academic research institutions.

2Neuroreader Sample Report
CategoryMedical Imaging Software
Description

Sample automated volumetric brain MRI report demonstrating Neuroreader's quantitative output including brain volume measurements, percentile rankings, Z-scores, and visual brain maps comparing patient scans against healthy normative databases. Provided on request to prospective customers.

3Neuroreader Patient Portal
CategoryPatient Education Resources
Description

Patient-facing resource explaining how Neuroreader works alongside standard brain MRI to provide deeper insights into brain health, including information on conditions supported, the analysis process, and how patients can request the service from their physicians.

4Neuroreader Case Studies
CategoryClinical Evidence Resources
Description

Published clinical case studies demonstrating Neuroreader's application in tracking Alzheimer's progression, frontotemporal dementia patterns, and longitudinal brain volume changes over time. Used to evidence clinical utility and outcomes for prospective customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-11-29
Description

Exclusive partnership to provide Neuroreader as sole volumetric brain analytics platform for landmark Beyond the Human Genome Project - a million-person brain health trial spanning ten years. Expected to enroll 100,000 participants yearly, resetting dementia treatment understanding worldwide.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-09
Description

Wide-ranging strategic partnership to expand FDA-cleared Neuroreader software through INFINITT's large North American customer base. INFINITT's enterprise imaging solutions serve over 6500 installations in 55 countries, providing significant distribution reach for Neuroreader's brain volumetric analysis.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-07-29
Description

Three-year R&D partnership supporting PhD research on AI and deep learning for neurodegenerative disease progression including Alzheimer's disease and Multiple Sclerosis. Daniel Ramsing Lund leads research combining established biomarkers with advanced deep learning techniques for brain MRI segmentation.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-01-07
Description

Professional medical group providing international radiology imaging services with extensive experience in neuroimaging and volumetric analysis. Provides quality assurance program for Neuroreader cases to improve accuracy and optimization of images required to generate reports.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool that directly competes with Neuroreader in the same clinical workflow for measuring hippocampus and other brain regions to support neurodegenerative disease diagnosis.

TypeDirect peer
Description

Belgian-US company providing AI-based MRI brain quantification software (icolung, icoaspects, ibrain) for multiple sclerosis, dementia, and other neurological conditions, with direct overlap in volumetric brain analysis targeting hospitals and imaging centers.

TypeEmerging player
Description

Finnish AI neuroimaging company offering brain MRI analysis tools (cDSI, cNeuro) for dementia and multiple sclerosis, addressing overlapping use cases in neurodegenerative disease quantification with a similar clinical customer base.

TypeEmerging player
Description

French medtech developing AI-based brain MRI biomarkers for multiple sclerosis and other neurological disorders, competing in adjacent brain volumetric and lesion quantification workflows serving neuroradiology practices.

TypeBroad incumbent
Description

Major clinical AI imaging platform with broad FDA-cleared radiology AI modules that increasingly include neuro workflows; a broad incumbent whose enterprise footprint could overlap with Brainreader's target customer base.

TypeBroad incumbent
Description

Enterprise AI imaging platform with FDA-cleared neurovascular modules (stroke detection) sold to similar hospital and health system customers; represents a well-capitalized incumbent expanding into broader neurology AI workflows.

TypeEmerging player
Description

AI medical imaging company focused on MRI image enhancement and quantification, addressing overlapping radiology customers and representing a potential adjacent or partial-overlap competitor for AI-based brain MRI analysis.

TypeEmerging player
Description

Provider of a curated marketplace and AI platform for medical imaging applications including brain analysis, targeting similar radiology and hospital customers through a channel/platform model.

TypeOthers
Description

Diagnostics and biomarker measurement company whose ultra-sensitive assays are used in neurodegenerative disease research and clinical trials; comparable in addressing the broader Alzheimer's and brain health biomarker market rather than directly competing on imaging AI.

TypeBroad incumbent
Description

Cloud-native AI medical imaging platform with FDA-cleared modules across multiple modalities including neuro MRI, serving similar hospital and radiology enterprise customers with a broader portfolio than Brainreader's brain-focused offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brainreader

Medical Imaging Softwarebrainreader.net

Brainreader is a Danish medtech company (founded 2011) that sells Neuroreader, an FDA-cleared AI software that quantifies 83 brain regions from routine MRI scans in under 10 minutes to support diagnosis and monitoring of neurodegenerative diseases for hospitals, imaging centers, and neurology/radiology practices.

What Brainreader does

Brainreader A/S is a Danish medtech company founded in 2011 by Jamila Ahdidan, PhD, that develops Neuroreader, an FDA-cleared and CE-marked AI-enabled software for automated brain volumetric analysis from routine MRI scans. The software segments and quantifies 83 brain regions in under 10 minutes, compares measured volumes against an FDA-cleared normative database of healthy brain tissue, and outputs reports containing volumes, percentiles, and Z-scores to support diagnosis and longitudinal monitoring of neurodegenerative conditions including Alzheimer's disease, mild cognitive impairment, traumatic brain injury, and frontotemporal dementia. Workflow integration is achieved via PACS mediation server or web upload with no hardware costs, enabling adoption as a routine MRI add-on.

The company sells to hospitals and health systems, imaging centers, neurology and radiology practices, and academic/research institutions via a pay-per-use model (approximately $70 per scan, reimbursable under CPT code 76377) and subscription licensing. Its core go-to-market combines direct enterprise sales — recently anchored by a US sales team led by Head of U.S. Sales Steve Green and a consulting CMO, Dr. Cyrus Raji — with channel distribution through INFINITT North America (access to 6,500+ PACS installations across 55 countries) and Rad Alliance. Notable clinical and research partners include UPMC, Medical College of Wisconsin, Washington University in St. Louis, Pacific Neuroscience Institute, and UCLA.

Brainreader is venture-backed (Insero, Investo Capital, Bevica Innovation, CBC Investment Group, and lead Series A investor Dahlgren Capital in May 2025 at $7.3M), ISO 13485:2016 certified, HIPAA-compliant, and operates from Aalborg, Denmark with a US headquarters in Tampa, Florida. A flagship commercial relationship is its exclusive partnership with Phenome Health on the Beyond the Human Genome Project, a ten-year, one-million-participant brain health trial.

Brainreader firmographics

Firmographics
Name
Brainreader
Legal name
Brainreader A/S
Website
https://brainreader.net
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Brainreader is a Danish medtech company (founded 2011) that sells Neuroreader, an FDA-cleared AI software that quantifies 83 brain regions from routine MRI scans in under 10 minutes to support diagnosis and monitoring of neurodegenerative diseases for hospitals, imaging centers, and neurology/radiology practices.
Ownership category
akta.pro rank

Brainreader industry classification

Industry
Product category
Medical Imaging Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • AI brain volumetrics
  • Medical imaging software
  • Neurodegenerative disease detection
  • MRI volumetric analysis
  • Brain health diagnostics

Where Brainreader is headquartered

Location

Headquarters

HQ city
Aalborg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Brainreader business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. SaaS/Per-Use Brain Volumetric Analysis: Pay-per-use model where healthcare facilities pay per MRI scan analyzed. Simple pay-per-use pricing with no hardware or setup costs. Also available via subscription model tailored to healthcare organization preferences.
  2. Subscription Licensing: Annual or multi-year subscription licensing options for hospitals, imaging centers, and radiology departments.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPay-per-use model
SubscriptionAnnualSubscription model for healthcare organizations

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Brainreader product offering

Product offering

Core offering

Brainreader develops Neuroreader, an FDA-cleared and CE-marked AI-powered medical software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. The platform provides objective volumetric measurements and statistical comparisons against an FDA-cleared normative database of healthy brain tissue, supporting detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, traumatic brain injury, and frontotemporal dementia. The software integrates directly into existing PACS workflows via web upload or on-site mediation server, eliminating the need for additional hardware.

Product overview

Brainreader offers a single unified product platform centered on Neuroreader, an FDA-cleared and CE-marked AI-powered medical software for automated brain volumetric analysis. The platform provides quantitative MRI analysis by measuring 83 brain regions and comparing results against an FDA-cleared normative database, generating automated reports in under 10 minutes. Supporting resources include patient-facing educational materials, sample reports, and published case studies demonstrating clinical applications for Alzheimer's disease, traumatic brain injury, and other neurodegenerative conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Neuroreader®: FDA-cleared and CE-marked AI-powered brain volumetric analysis software that quantifies 83 brain regions from routine MRI scans in less than 10 minutes for neurodegenerative disease detection.

Products and services

  • Neuroreader FDA-cleared and CE-marked AI-powered brain volumetric analysis software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. Provides objective quantitative measurements, normative comparisons via an FDA-cleared healthy-brain database, and automated reports to support diagnosis and monitoring of neurodegenerative diseases including Alzheimer's, dementia, and traumatic brain injury. Targeted at hospitals, imaging centers, neurology and radiology practices, and academic research institutions.
  • Neuroreader Sample Report Sample automated volumetric brain MRI report demonstrating Neuroreader's quantitative output including brain volume measurements, percentile rankings, Z-scores, and visual brain maps comparing patient scans against healthy normative databases. Provided on request to prospective customers.
  • Neuroreader Patient Portal Patient-facing resource explaining how Neuroreader works alongside standard brain MRI to provide deeper insights into brain health, including information on conditions supported, the analysis process, and how patients can request the service from their physicians.
  • Neuroreader Case Studies Published clinical case studies demonstrating Neuroreader's application in tracking Alzheimer's progression, frontotemporal dementia patterns, and longitudinal brain volume changes over time. Used to evidence clinical utility and outcomes for prospective customers.

Quantifiable outcome

  • Reports generated in under 10 minutes, significantly faster than manual expert anatomical tracings which take 30+ minutes
  • +3 more outcomes

Companies that use Brainreader

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Brainreader technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature3 records

Brainreader partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and supporting.

  • Phenome HealthflagshipStrategic or Co-development Partner · 29 November 2022Exclusive partnership to provide Neuroreader as sole volumetric brain analytics platform for landmark Beyond the Human Genome Project - a million-person brain health trial spanning ten years. Expected to enroll 100,000 participants yearly, resetting dementia treatment understanding worldwide.
  • INFINITT North AmericacoreChannel Partner/ Reseller/ Distributor · 9 June 2022Wide-ranging strategic partnership to expand FDA-cleared Neuroreader software through INFINITT's large North American customer base. INFINITT's enterprise imaging solutions serve over 6500 installations in 55 countries, providing significant distribution reach for Neuroreader's brain volumetric analysis.
  • Aalborg UniversitysupportingStrategic or Co-development Partner · 29 July 2021Three-year R&D partnership supporting PhD research on AI and deep learning for neurodegenerative disease progression including Alzheimer's disease and Multiple Sclerosis. Daniel Ramsing Lund leads research combining established biomarkers with advanced deep learning techniques for brain MRI segmentation.
  • Rad AlliancesupportingChannel Partner/ Reseller/ Distributor · 7 January 2019Professional medical group providing international radiology imaging services with extensive experience in neuroimaging and volumetric analysis. Provides quality assurance program for Neuroreader cases to improve accuracy and optimization of images required to generate reports.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Brainreader competitors and assessment

Company assessment

Direct peers

  • Cortechs.ai: Developer of NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool that directly competes with Neuroreader in the same clinical workflow for measuring hippocampus and other brain regions to support neurodegenerative disease diagnosis.
  • icometrix: Belgian-US company providing AI-based MRI brain quantification software (icolung, icoaspects, ibrain) for multiple sclerosis, dementia, and other neurological conditions, with direct overlap in volumetric brain analysis targeting hospitals and imaging centers.

Emerging players

  • Combinostics: Finnish AI neuroimaging company offering brain MRI analysis tools (cDSI, cNeuro) for dementia and multiple sclerosis, addressing overlapping use cases in neurodegenerative disease quantification with a similar clinical customer base.
  • Pixyl: French medtech developing AI-based brain MRI biomarkers for multiple sclerosis and other neurological disorders, competing in adjacent brain volumetric and lesion quantification workflows serving neuroradiology practices.
  • Subtle Medical: AI medical imaging company focused on MRI image enhancement and quantification, addressing overlapping radiology customers and representing a potential adjacent or partial-overlap competitor for AI-based brain MRI analysis.
  • Blackford Analysis: Provider of a curated marketplace and AI platform for medical imaging applications including brain analysis, targeting similar radiology and hospital customers through a channel/platform model.

Broad incumbents

  • Aidoc: Major clinical AI imaging platform with broad FDA-cleared radiology AI modules that increasingly include neuro workflows; a broad incumbent whose enterprise footprint could overlap with Brainreader's target customer base.
  • Viz.ai: Enterprise AI imaging platform with FDA-cleared neurovascular modules (stroke detection) sold to similar hospital and health system customers; represents a well-capitalized incumbent expanding into broader neurology AI workflows.
  • Arterys: Cloud-native AI medical imaging platform with FDA-cleared modules across multiple modalities including neuro MRI, serving similar hospital and radiology enterprise customers with a broader portfolio than Brainreader's brain-focused offering.

Others

  • Quanterix: Diagnostics and biomarker measurement company whose ultra-sensitive assays are used in neurodegenerative disease research and clinical trials; comparable in addressing the broader Alzheimer's and brain health biomarker market rather than directly competing on imaging AI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Brainreader social profiles

Digital presence

Brainreader compliance and trust

Trust signal

Compliance4 records

Brainreader financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brainreader leadership team

Management profile

Number of profiles

Profiles7 records

Brainreader subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Brainreader funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brainreader M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brainreader

What does Brainreader do?

Brainreader develops Neuroreader, an FDA-cleared and CE-marked AI-powered medical software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. The platform provides objective volumetric measurements and statistical comparisons against an FDA-cleared normative database of healthy brain tissue, supporting detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, traumatic brain injury, and frontotemporal dementia. The software integrates directly into existing PACS workflows via web upload or on-site mediation server, eliminating the need for additional hardware.

Is Brainreader a public or private company?

Brainreader is a private company. It is classified as venture growth investor backed and is currently operating.

When was Brainreader founded?

Brainreader was founded in 2011. It employs 11 to 50 people.

Where is Brainreader based?

Brainreader is headquartered in Aalborg, Denmark, in the Europe region.

How does Brainreader make money?

Two revenue lines are on record. SaaS/Per-Use Brain Volumetric Analysis are the primary driver. The others are subscription Licensing.

Who are Brainreader's main competitors?

Direct peers on record are Cortechs.ai and icometrix. Emerging players are Combinostics, Pixyl, Subtle Medical and Blackford Analysis. Broad incumbents are Aidoc, Viz.ai and Arterys. Quanterix is listed as an others.

Does Brainreader have an API?

No public API is recorded for Brainreader.

What industry is Brainreader in?

Brainreader's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBrainreader and Lovell Government Services Partner to Expand Federal Access to Neuroreader® for VA,DoD, and IHSBrainreader and Lovell Government Services announced a partnership to expand federal access to Neuroreader, an FDA-cleared brain MRI analysis platform, for VA, DoD, and IHS. Lovell will serve as the SDVOSB vendor of record, listing the software through the GSA Multiple Award Schedule. The partnership aims to streamline acquisition and help federal agencies meet SDVOSB procurement goals.LinkedInAI in Medical Imaging - June Round-upJune 2025 saw continued momentum across the medical imaging AI sector with multiple funding rounds, acquisitions, and regulatory approvals. RadNet expanded its DeepHealth portfolio by acquiring Singapore-based See-Mode Technologies, adding FDA-cleared AI tools for thyroid and breast ultrasound, while Brainreader and DESKi collectively raised over $13 million in funding to scale their respective AI platforms. Germany approved a national lung cancer screening programme from April 2026, Norway launched its first autonomous AI chest X-ray pilot, and several companies including Viz.ai, Avicenna.AI, Lunit, and Us2.ai secured new regulatory clearances across the US, Europe, and Asia.BrainreaderBrainreader Raises $7.3M to Expand AI-Powered Brain DiagnosticsDanish medtech company Brainreader A/S completed a USD 7.3 million funding round to expand its AI-powered brain diagnostic platform Neuroreader, aiming to enhance global clinical deployment. The funding will support scaling operations in the US healthcare market, and developing new features and applications.DahlgrencapDahlgren Capital Leads €6.6M Investment in Danish Medtech Innovator BrainreaderDahlgren Capital led a €6.6M investment in Danish medtech firm Brainreader, with existing shareholder Investo Capital continuing to back the company. The funds will accelerate Brainreader's commercial expansion, especially in the U.S., and support development of new features. Neuroreader, the company's AI-powered brain MRI analysis tool, is CE-marked and FDA-cleared.Tech.euBrainreader raises €6.6M to expand AI-driven neurological diagnostic platformDanish medtech company Brainreader raised €6.6 million to expand its AI-driven Neuroreader diagnostic platform. The CE-marked, FDA-cleared software automates brain MRI volumetric analysis for conditions like Alzheimer's and traumatic brain injury. The round, led by Dahlgren Capital, supports US market growth and new clinical features.YahooBrainreader secures €6.6m for brain diagnostic commercialisationDanish medtech Brainreader secured €6.6m ($7.3m) led by Dahlgren Capital to commercialize Neuroreader, its AI-based brain diagnostic software. The platform processes MRI scans to aid diagnosis of neurodegenerative conditions and TBI, with CE and FDA clearances. The company plans to expand faster and reach more clinics worldwide.GlobeNewswireBlackford and Brainreader Announce Commercial Partnership to Bring Advanced Medical Image Analysis and Diagnostic Assessment Tools to Healthcare ProvidersBlackford and Brainreader announced a commercial partnership to integrate Brainreader's Neuroreader brain volumetric software into Blackford's medical imaging AI platform. The FDA-cleared and CE-marked software analyzes brain MRI images to measure volumes, aiding diagnosis of neurodegenerative diseases like Alzheimer's. The partnership aims to provide healthcare providers with advanced diagnostic tools within their existing workflows.GlobeNewswireBlackford and Brainreader Announce Commercial Partnership to Bring Advanced Medical Image Analysis and Diagnostic Assessment Tools to Healthcare ProvidersBlackford and Brainreader announced a commercial partnership to integrate Brainreader's Neuroreader brain volumetric software into Blackford's AI platform. Neuroreader, FDA cleared and CE marked, analyzes brain MRI images to measure volumes and assist in diagnosing neurodegenerative diseases like Alzheimer's. The partnership aims to provide healthcare providers with advanced diagnostic tools within their existing workflow.PR NewswireBrainreader and Phenome Health Nearing Exclusive RelationshipBrainreader Inc. announced it is in advanced negotiations to become the sole provider of Neuroreader® volumetric brain analytics software for Phenome Health's landmark one-million-person trial focused on dementia and brain health, with Dr. Lee Hood as a key figure in the initiative. The trial, targeting a 2023 launch and designed to examine approximately 100,000 participants yearly, aims to reset data, science, and clinical practice around dementia treatment globally. Dr. Hood noted that Neuroreader® demonstrated superior detail and efficiency compared to alternative brain volumetric software options reviewed.